Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids
Source Ouchi et al., 2019 · Cincinnati Children's Hospital Medical Center · 10.1016/j.cmet.2019.05.007
Abstract
This protocol describes the generation of multi-cellular human liver organoids (HLOs) from pluripotent stem cells, containing hepatocyte-like, stellate-like, and Kupffer-like cells. The organoids recapitulate progressive features of steatohepatitis including steatosis, inflammation, and fibrosis when exposed to free fatty acids, and can model genetic liver diseases such as Wolman disease.
Protocol overview
22 steps across 5 phases
- 1 Cell dissociation and plating
- 2 Day 1 endoderm induction
- 3 Day 2 endoderm induction
- 4 Day 3 endoderm induction
- 5 Days 4-6 foregut specification
- 1 Spheroid collection and embedding
- 2 Retinoic acid treatment
- 3 Switch to hepatocyte maturation medium
- 4 HLO maturation culture
- 1 Prepare organoids for FFA treatment
- 2 Oleic acid treatment initiation
- 3 Steatohepatitis phenotype assessment (Day 3)
- 4 Fibrosis marker assessment (Day 5-7)
- 1 Prepare Wolman disease organoids
- 2 FGF19 treatment
- 3 Assess FGF19 rescue at day 7
- 4 Viability assessment (Day 12)
- 1 Prepare fibronectin-coated AFM substrate
- 2 Transfer organoids to AFM substrate
- 3 AFM cantilever setup
- 4 AFM indentation measurement
- 5 Young's modulus calculation
Full SOP
Create a free account to access this protocol
Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.
Create free accountAlready registered? Log in
Attribution
This SOP was authored by Organthis based on the published method in Ouchi et al., 2019. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.
This wording is awaiting legal review.
Something wrong with this entry? Report an issue with this protocol